GSK, european union and Endometrial Cancer
Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK (NYSE:GSK – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” ...
GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...
The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...
GSK PLC GSK shares inched down 0.22% to £13.56 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 0.04% to 8,545.13. Supported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback